Pfizer.lithyemhosting.com

lipitor $12.4 billion –2%
xalatan/xalacom $1.7 billion +9%
Lipitor, prescribed to treat or prevent cardiovascular disease, is the world’s Xalatan is the world’s leading branded treatment for ocular hypertension largest-sel ing branded pharmaceutical. In 2008, Pfizer announced an and open-angle glaucoma, the second-most-prevalent cause of blindness agreement with generics manufacturer Ranbaxy to settle substantial y all in the world. Xalatan, a once-a-day therapy, reduces pressure in the eye, their patent litigation worldwide involving Lipitor. Ranbaxy will have a which may cause damage to the optic nerve if not treated. Xalacom, license to sell generic versions of Lipitor and Caduet (a combination of a fixed combination of Xalatan and the beta-blocker timolol, is an option Lipitor and Pfizer’s hypertension medicine, Norvasc) in the United States for patients who would benefit from additional eye pressure lowering effective November 30, 2011. The settlement provides substantial certainty compared to Xalatan alone. Xalacom is approved only in markets outside regarding the potential date for entry of a generic version of Lipitor in the U.S. (See page 18 for more information on Pfizer’s co-promotion the U.S. In addition, the agreement provides a license for Ranbaxy to agreement with Bausch & Lomb covering Xalatan.) sell generic versions of Lipitor on varying dates in seven additional countries and resolves disputes regarding Lipitor in four other countries. (See page 12 for more information on Lipitor.) Detrol/Detrol la $1.2 billion +2%
Detrol is the world’s leading prescription medicine for overactive bladder,
a condition that affects up to 100 mil ion people around the world. $2.6 billion +41%
Detrol LA, the once-daily, extended-release formulation, has become the Lyrica is a safe and effective option for many patients to treat some standard of care for this vastly undertreated condition.
neurologic pain conditions and is one of Pfizer’s fast-growing medicines. Lyrica is approved in the U.S. for painful diabetic peripheral neuropathy and postherpetic neuralgia, the pain that often fol ows shingles, and for neuropathic pain outside the U.S. Lyrica also is prescribed in many markets zyvox $1.1 billion +18%
for partial onset seizures in adults who are already taking one or more Zyvox, which extends Pfizer’s record of innovation in antibiotics, is the antiseizure medicines. Lyrica also is approved in a number of major markets world’s best-sel ing branded medicine to treat serious skin or lung infections for the management of fibromyalgia and Generalized Anxiety Disorder, caused by gram-positive bacteria, including methicil in-resistant a common and chronic psychiatric condition characterized by excessive, Staphylococcus aureus, commonly known as MRSA. Zyvox works against uncontrol able and often irrational worry about everyday events. (See MRSA by a unique mechanism of action, minimizing the potential for cross-resistance. Because it is available in both oral and intravenous forms, and is approved for adults and children, Zyvox offers doctors considerable flexibility in the transition of patients from hospital settings to home or celebrex
$2.5 billion +9%
In 2009 Celebrex marks 10 years of continuous availability to patients. It is one of the most studied arthritis pain medicines available today and has been evaluated in more than 25,000 patients for over 15 years. geoDon/zelDox $1.0 billion +18%
Celebrex is a nonsteroidal anti-inflammatory drug (NSAID), which Geodon (marketed outside the U.S. as Zeldox) is an atypical antipsychotic has seven indications in the U.S. It is prescribed for the management approved in more than 85 markets for treating schizophrenia, as well as for of the signs and symptoms—including pain and inflammation— acute mania and mixed episodes associated with bipolar disorder. Geodon of osteoarthritis, rheumatoid arthritis in adults and juveniles, acute offers dosing flexibility, proven efficacy and a favorable metabolic profile.
pain in adults, menstrual pain and ankylosing spondylitis, a form of arthritis that largely affects the spine, and for the prevention of familial adenomatous polyposis, an inherited condition where multiple polyps form in the large intestine. While the Celebrex U.S. product label genotropin $898 million +6%
contains the same cardiovascular and gastrointestinal warning as all Genotropin is the world’s leading human recombinant growth hormone, prescription NSAIDs, Celebrex offers unique benefits to patients, accounting for about one-third of the total market. Available for more including a favorable gastrointestinal tolerability profile and the ability than 20 years, Genotropin is approved by the FDA to treat growth failure to be used in combination with low-dose aspirin. in children with growth hormone deficiency, children born small for gestational age, children with Prader-Wil i syndrome, girls with Turner syndrome and adults with growth hormone deficiency. Pfizer provides norvasc $2.2 billion –25%
a great deal of support for patients needing Genotropin, including access to personalized counseling, continued investment in drug and Norvasc is the most prescribed brand name high blood pressure medicine delivery-device innovation, secure sources of supply, and high integrity worldwide and began to face generic competition in 2007. Pfizer introduced in manufacturing, marketing and distribution.
its own generic version of Norvasc through Greenstone, its U.S. generics unit, and continues to make the branded version widely available.
sutent $847 million +46%
viagra $1.9 billion +10%
Sutent, a breakthrough cancer treatment, is used by oncologists to treat two types of cancer—advanced renal cell carcinoma and imatinib- One of the best-known pharmaceutical brands, Viagra is the world’s leading resistant or -intolerant gastrointestinal stromal tumor. Studies are treatment for erectile dysfunction, a position it has held every year since under way to explore Sutent’s effectiveness against other types of cancers: its introduction in 1998. Viagra is backed by far more patient experience breast, non-small cell lung, liver, prostate and advanced colorectal. than any competing treatment, and has been shown to work safely and (See page 12 for more information on Sutent.) effectively in men of all ages, men who have difficulty all of the time or just some of the time, and men with other health issues, such as hypertension, depression and diabetes.
www.pfizer.com/annual
chantix/champix $846 million –4%
zithromax/zmax $429 million –2%
Chantix, marketed outside the U.S. as Champix, is a non-nicotine-based Zithromax, Pfizer’s wel -known oral antibiotic, has an extended-release therapy for smoking cessation. Chantix/Champix has been launched version branded as Zmax (azithromycin extended release). Zmax is the in all major markets, including China, the country that has the largest first single-dose oral antibiotic for adults and uses innovative microsphere number of smoking-related deaths. (See page 13 for more information technology to deliver a complete course of therapy in a single 2-gram dose. This approach improves patient compliance and minimizes the threat of antibiotic resistance. Zithromax and Zmax are general y used to treat bacterial respiratory infections, including sinusitis and pneumonia.
vfenD $743 million +18%
Vfend is the world’s best-sel ing systemic antifungal. It is an important
medicine for treating often deadly systemic fungal infections such $336 million +67%
as invasive aspergil osis and candidemia, which are often seen in Revatio treats pulmonary arterial hypertension (PAH), a rare but often immunocompromised patients. Vfend can be administered oral y devastating disorder characterized by continuous high blood pressure in the pulmonary arteries, leading to heart failure and premature death. The prognosis is comparable to Stage IV lung cancer. An oral phosphodiesterase type 5 (PDE5) inhibitor, Revatio was the first drug with this mode of action to be approved worldwide for patients $589 million +4%
with PAH. (See page 33 for more information on Revatio.) Caduet is a single-pil , once-a-day combination therapy of Lipitor and Norvasc, and is designed to fit the needs of patients with two significant risk factors for serious cardiovascular disease.
relpax $321 million +2%
Relpax provides relief from moderate and severe migraine pain and
camptosar
associated symptoms, such as nausea and sensitivity to light. Clinical data $563 million –42%
show that Relpax works fast, in as little as 30 minutes for some people, Camptosar is a foundation treatment for colorectal cancer used when the and helps most people return to routine activities within two hours. Studies cancer is advanced and spreading. Pfizer’s U.S. basic patent for Camptosar also show that with Relpax more people were pain free, for up to 24 hours, than those taking a competitive product.
zoloft $539 million +2%
selzentry/celsentri $46 million +814%
Since 2006 Pfizer has faced generic competition for Zoloft in the U.S. Selzentry (marketed outside the U.S. as Celsentri) is the first of a new However, Pfizer retains exclusive marketing rights in several countries, class of oral HIV treatments that stop the virus on the outside surface including Japan, where this antidepressant medicine is branded as J Zoloft.
of the cell instead of fighting it inside the cell like other classes of HIV medicines. Selzentry is used in combination with other antiretroviral agents for treatment-experienced adult patients who are infected with only CCR5-tropic HIV-1 and who have evidence of viral replication and HIV-1 aricept $482 million* +20%
strains resistant to multiple antiretroviral agents. A simple diagnostic test Aricept is the top-sel ing medicine in the Alzheimer’s disease market. Its is used to confirm if a patient has the common strain of HIV that may success is built on 15 years of clinical evidence supporting its efficacy and respond to Selzentry therapy. Conditional y approved by the FDA in 2007, tolerability. Aricept is approved in the U.S. for mild, moderate and severe Selzentry gained full regulatory approval in 2008 in the U.S. and is currently forms of Alzheimer’s disease. Pfizer co-promotes Aricept with its discoverer eraxis/ecalta $43 million +109%
aromasin $465 million +16%
Launched in 2007, and building on Pfizer’s strength in combating infection, Aromasin, an aromatase inhibitor, is a hormonal therapy approved Eraxis (marketed in Europe as Ecalta) is an antifungal agent indicated for for postmenopausal women who have had estrogen-receptor positive the treatment of Candida infections in the blood, abdomen and esophagus. early-stage breast cancer and who have taken tamoxifen for two or It has the benefit of no known drug interactions. three years. While tamoxifen blocks estrogen from attaching itself to breast cancer cel s, Aromasin helps stop the production of estrogen in postmenopausal women, further reducing the risk of estrogen-dependent co-promoteD meDicines
tumor growth. First approved by U.S. and E.U. regulators in 1999, Aromasin is now available in nearly all major markets.
Pfizer also co-promotes Rebif, a treatment for relapsing forms of multiple sclerosis, and Spiriva, a medicine for chronic obstructive pulmonary disease, with their discoverers—EMD Serono, Inc., and Boehringer Ingelheim, respectively. Sales for these medicines are reported through these co-promotion partners. *Represents direct sales under license agreement with Eisai Co., Ltd.
www.pfizer.com/annual

Source: http://pfizer.lithyemhosting.com/pdf/key_medicines2008.pdf